Clinical Trials Directory

Trials / Completed

CompletedNCT01078220

Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)

A Post-licensure Surveillance Program for the Safety of GARDASIL™ in a Managed Care Organization Setting

Status
Completed
Phase
Study type
Observational
Enrollment
189,629 (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
Female
Age
9 Years
Healthy volunteers
Accepted

Summary

This is a post-licensure safety surveillance program to detect potential safety signals in subjects, from the managed care organizations database, who have used GARDASIL™.

Conditions

Timeline

Start date
2007-02-06
Primary completion
2010-12-13
Completion
2010-12-13
First posted
2010-03-02
Last updated
2017-07-11
Results posted
2012-01-09

Source: ClinicalTrials.gov record NCT01078220. Inclusion in this directory is not an endorsement.

Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDAS (NCT01078220) · Clinical Trials Directory